Funding for this research was provided by:
Canadian Institutes of Health Research
Article History
Received: 24 August 2021
Accepted: 15 October 2021
First Online: 3 November 2021
Declarations
:
: BW reports consulting fees from Maple Health Group, outside the submitted work. DWC reports consulting/advisory fees from Agendia, AstraZeneca, Dynamo Therapeutics, Eisai, Exact Sciences, Gilead, GlaxoSmithKline, Merck, Novartis, Pfizer, Puma Biotechnology, and Roche; research support (to institution) from GlaxoSmithKline, Inivata, Merck, Pfizer and Roche; and intellectual property including methods of treating cancers characterized by a high expression level of spindle and kinetochore-associated complex subunit 3 (ska3) gene (US62/675,228), all outside of the submitted work.